GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (OTCPK:GENSF) » Definitions » Price-to-Owner-Earnings

Genus (GENSF) Price-to-Owner-Earnings : 28.29 (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Genus Price-to-Owner-Earnings?

As of today (2024-05-05), Genus's share price is $28.01. Genus's Owner Earnings per Share (TTM) ended in Jun. 2023 was $0.99. It's Price-to-Owner-Earnings for today is 28.29.


The historical rank and industry rank for Genus's Price-to-Owner-Earnings or its related term are showing as below:

GENSF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.06   Med: 31.56   Max: 142.29
Current: 28.17

During the past 13 years, the highest Price-to-Owner-Earnings of Genus was 142.29. The lowest was 12.06. And the median was 31.56.


GENSF's Price-to-Owner-Earnings is ranked better than
57.93% of 164 companies
in the Biotechnology industry
Industry Median: 33.89 vs GENSF: 28.17

As of today (2024-05-05), Genus's share price is $28.01. Genus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.64. Therefore, Genus's PE Ratio for today is 43.83.

As of today (2024-05-05), Genus's share price is $28.01. Genus's EPS without NRI for the trailing twelve months (TTM) ended in was $0.87. Therefore, Genus's PE Ratio without NRI for today is 32.08.

During the past 13 years, Genus's highest PE Ratio without NRI was 70.80. The lowest was 19.85. And the median was 30.68.


Genus Price-to-Owner-Earnings Historical Data

The historical data trend for Genus's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genus Price-to-Owner-Earnings Chart

Genus Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.85 33.70 42.15 42.25 32.53

Genus Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 42.25 - 32.53 -

Competitive Comparison of Genus's Price-to-Owner-Earnings

For the Biotechnology subindustry, Genus's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genus's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genus's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Genus's Price-to-Owner-Earnings falls into.



Genus Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Genus's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=28.01/0.99
=28.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genus  (OTCPK:GENSF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Genus Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Genus's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Genus (GENSF) Business Description

Traded in Other Exchanges
Address
Matrix House, Basing View, Basingstoke, Hants, GBR, RG21 4DZ
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.